A retrospective propensity-matched comparison of Micell Technologies Inc.'s Micell’s MiStent sirolimus-eluting absorbable polymer coronary stent system to Abbott Vascular's popular Xience V everolimus-eluting stent suggests that MiStent has a good chance of outperforming Xience in the DESSOLVE III randomized trial.
MiStent elutes sirolimus, a common anti-inflammatory drug, from polylactic-co-glycolic acid (PLGA), a common biodegradable polymer coating, but whereas most drug-eluting...